

Supplementary data

Characterization and Quantitative Analysis of Phenylpropanoid Amides in Eggplant (*Solanum melongena* L.) by High Performance Liquid Chromatography Coupled with Diode Array Detection and Hybrid Ion Trap-Time of Flight Mass Spectrometry

Jing Sun,^{†,‡,§} Yue-Lin Song,^{†,§} Jing Zhang,^{†,‡} Zheng Huang,^{†,‡} Hui-Xia Huo,^{†,‡} Jiao Zheng,[†] Qian Zhang,[†] Yun-Fang Zhao,[†] Jun Li,^{*,†} and Peng-Fei Tu^{*,†}

[†]Modern Research Center for Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, People's Republic of China

[‡]School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, People's Republic of China

Corresponding Author:

^{*}(J.L.) Tel/Fax: 86-10-64286350, E-mail: drlj666@163.com;

^{*}(P.-F.T.) Tel/Fax: 86-10-82802750, E-mail: pengfeitu@163.com.

[#] J.S. and Y.-L.S. contributed equally to this research.

No.	Content
Figure S1	Mass spectra (MS ¹ , MS ² , and MS ³) (A) and the proposed schematic of mass fragmentation pathways of <i>N</i> - <i>trans</i> - <i>p</i> -coumaroylputrescine (compound 8) (B).
Figure S2	Mass spectra (MS ¹ , MS ² , and MS ³) (A) and the proposed schematic of mass fragmentation pathways of <i>N</i> ¹ , <i>N</i> ⁸ -dicaffeoylspermidine (compound 17) (B).
Figure S3	Mass spectra (MS ¹ , MS ² , and MS ³) (A) and the proposed schematic of mass fragmentation pathways of <i>N</i> ¹ -caffeooyl- <i>N</i> ⁸ -hydrocaffeooylspermidine (compound 15) (B).
Figure S4	Mass spectra (MS ¹ , MS ² , and MS ³) (A) and the proposed schematic of mass fragmentation pathways of <i>N</i> ¹ , <i>N</i> ⁸ -dicaffeoylspermidine (compound 13) (B).
Figure S5	Mass spectra (MS ¹ , MS ² , and MS ³) (A) and the proposed schematic of mass fragmentation pathways of <i>N</i> ¹ -hydrocaffeooyl- <i>N</i> ⁸ -caffeooylspermidine (compound 16) (B).
Table S1	Calibration Curves, Linear Ranges, LODs, and LLOQs for the Ten Analytes
Table S2	Validation Data of HPLC-UV Quantitative Method for the Ten Analytes




Figure S1. Mass spectra (MS^1 , MS^2 , and MS^3) (A) and the proposed schematic of mass fragmentation pathway of *N-trans-p*-coumaroylputrescine (compound 8) (B).




Figure S2. Mass spectra (MS^1 , MS^2 , and MS^3) (A) and the proposed schematic of mass fragmentation pathway of N^1,N^8 -dicaffeoylspermidine (compound 17) (B).




Figure S3. Mass spectra (MS¹, MS², and MS³) (A) and the proposed schematic of mass fragmentation pathway of *N*¹-caffeyl-*N*⁸-hydrocaffeoylspermidine (compound 15) (B).




Figure S4. Mass spectra (MS¹, MS², and MS³) (A) and the proposed schematic of mass fragmentation pathway of *N*¹,*N*⁸-dicaffeoylspermidine (compound 13) (B).




Figure S5. Mass spectra (MS¹, MS², and MS³) (A) and the proposed schematic of mass fragmentation pathway of *N*¹-hydrocaffeoyl-*N*⁸-caffeoyspermidine (compound **16**) (B).

Table S1. Calibration Curves, Linear Ranges, LODs, and LLOQs for the Ten Analytes

analyte ^a	calibration curve	correlation coefficient (R^2)	linear range ($\mu\text{g/mL}$)	LOD ($\mu\text{g/mL}$)	LLOQ ($\mu\text{g/mL}$)
6	$y = 11768x - 755.3$	0.9996	0.14 – 6.95	0.06	0.10
11	$y = 114775x - 13829$	0.9995	2.06 – 103.24	0.03	0.10
12	$y = 10929x - 1467$	0.9996	0.25 – 12.57	0.06	0.10
24	$y = 8125.6x - 2038.5$	0.9996	0.61 – 30.48	0.14	0.27
25	$y = 13208x - 8083$	0.9995	1.62 – 81.23	0.15	0.24
26	$y = 10227x - 1585.6$	0.9996	0.38 – 9.58	0.09	0.22
32	$y = 12077x - 4018.8$	0.9996	0.75 – 37.67	0.19	0.30
33	$y = 12004x - 5795.6$	0.9995	1.18 – 58.93	0.14	0.21
36	$y = 7400.8x - 519.39$	0.9996	0.21 – 5.28	0.03	0.09
37	$y = 10009x - 153.81$	0.9992	0.11 – 1.02	0.04	0.08

^a The notation for compounds refers to Figures 4 & 5.

Table S2. Validation Data of HPLC-UV Quantitative Method for the Ten Analytes

analyte ^a	precision (RSD, %)		repeatability (RSD, %; n=6)	stability (RSD, %; n=6)	recovery (n=3, %)	
	intra-day (n=6)	inter-day (n=6)			mean	RSD
6	0.08	0.69	3.55	0.83	96.17	1.91
					103.69	1.08
					97.76	1.37
11	0.04	0.38	3.15	0.22	102.87	3.79
					98.66	1.91
					104.89	0.80
12	0.04	0.31	3.35	0.92	101.16	3.63
					98.65	4.41
					99.91	3.09
24	0.03	0.21	1.89	0.52	103.54	1.13
					100.55	0.30
					104.76	0.47
25	0.03	0.18	1.25	0.20	101.52	1.81
					100.77	0.29
					100.78	0.35
26	0.04	0.17	2.11	1.46	102.48	2.62
					103.62	1.40
					99.70	1.81
32	0.05	0.19	2.46	0.49	104.57	0.29
					101.33	2.98
					103.90	1.29
33	0.04	0.19	2.22	0.26	104.41	0.57
					104.99	1.29
					102.72	0.45
36	0.03	0.06	2.25	3.96	98.10	0.32
					105.00	0.38
					105.00	0.16
37	0.02	0.04	4.44	3.77	101.97	2.33
					99.16	1.98
					104.33	2.32

^aThe analytes in Table S2 are coded the same as those in Table S1.